Garfield Alastair 4

4 · RHYTHM PHARMACEUTICALS, INC. · Filed Feb 13, 2026

AI-generated summary of this filing

Updated Feb 13, 2026

Rhythm Pharmaceuticals (RYTM) CSO Alastair Garfield Receives 41,650 RSUs

What Happened

Alastair Garfield, Chief Scientific Officer of Rhythm Pharmaceuticals (RYTM), received awards totaling 41,650 restricted stock units (16,650 + 25,000) on February 11, 2026. The grants were recorded at $0.00 (i.e., awards/derivatives) and represent contingent rights to common shares rather than open‑market purchases or sales. These are compensation/retention awards and do not reflect an immediate purchase or sale of shares.

Key Details

Transaction date: February 11, 2026; Filing date (Form 4): February 13, 2026 — appears timely (within the usual 2‑business‑day window).
Grant price: $0.00 (awarded RSUs/derivative).
Total RSUs granted: 41,650 (16,650 + 25,000).
Shares owned after transaction: not disclosed in the provided filing details.
Footnotes of note:
- F1: Each RSU converts to one common share upon vesting.
- F2: RSUs vest 25% on each of Feb 1 in 2027, 2028, 2029 and 2030; no expiration date.
- F3: The filing also references stock options granted Feb 11, 2026 that vest in 16 equal installments every three months of continued service (details/amounts not specified here).

Context

These were awards (A), not purchases (P) or sales (S). RSUs are contingent on continued service and vest over time, so they are standard executive compensation rather than a direct market bet. They do not indicate an immediate change in share ownership until vested and issued.

Form 4

Period: 2026-02-11

Chief Scientific Officer

Transactions

Award
Restricted Stock Units
[F1][F2]
2026-02-11+16,650→ 16,650 total
→ Common Stock (16,650 underlying)
Award
Stock Options (Right to Buy)
[F3]
2026-02-11+25,000→ 25,000 total
Exercise: $98.47Exp: 2036-02-10→ Common Stock (25,000 underlying)

Footnotes (3)

[F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
[F2]The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.
[F3]The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

Signature

/s/ Stephen Vander Stoep, attorney-in-fact for Alastair Garfield|2026-02-13

1 file